Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Small Cell Lung Carcinoma 3Breast Neoplasms 2Triple Negative Breast Neoplasms 1Intracranial Germ Cell CNS Tumor, Childhood 1

Interventions

Carboplatin 79pembrolizumab 64Paclitaxel 64Cyclophosphamide 47Capecitabine 34Doxorubicin 31Taxes 28130-nm albumin-bound paclitaxel 28Albumin-Bound Paclitaxel 27Gemcitabine 20atezolizumab 18Epirubicin 18Cisplatin 18Bevacizumab 18olaparib 17sacituzumab govitecan 15Docetaxel 15eribulin 14toripalimab 13durvalumab 13camrelizumab 13Drug Therapy 12apatinib 9Trastuzumab 9Radiotherapy 9Specimen Handling 8Magnetic Resonance Spectroscopy 8Biopsy 8tislelizumab 7talazoparib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Triple Negative Breast Neoplasms × EC regimen × Clear all
NCT05834582 2023-04-28

Neoadjuvant Fluzoparib in Germline BRCA-mutated Three-negative Breast Cancer Breast Cancer

The First Affiliated Hospital with Nanjing Medical University

Phase 2 Unknown
60 enrolled
Breast

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡